Axim Biotechnologies, Inc (AXIM) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
6191 CORNERSTONE COURT, E SAN DIEGO, CA 92121 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2023 MRQ | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 47 | 453 | 457 | 512 | 1,806 | 2,058 | |||
| Cash and cash equivalents | 47 | 453 | 457 | 512 | 1,806 | 2,058 | |||
| Receivables | 321 | 5 | 5 | ||||||
| Inventory, net of allowances, customer advances and progress billings | 488 | 10 | 9 | ||||||
| Inventory | 488 | 10 | 9 | ||||||
| Prepaid expense | 43 | ||||||||
| Other current assets | 14 | 20 | |||||||
| Other undisclosed current assets | 164 | 256 | 319 | 202 | 41 | ||||
| Total current assets: | 104 | 637 | 713 | 1,639 | 2,023 | 2,113 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 20 | 77 | 131 | ✕ | ✕ | ||||
| Property, plant and equipment | 94 | 117 | 104 | 2 | |||||
| Intangible assets, net (including goodwill), including: | 3,989 | 4,384 | 2,458 | 51 | |||||
| Goodwill | 2,458 | ||||||||
| Intangible assets, net (excluding goodwill) | 12,249 | 8,654 | 51 | ||||||
| Other undisclosed intangible assets, net (including goodwill) | (8,259) | (4,270) | |||||||
| Prepaid expense | 5 | 7 | 7 | ||||||
| Other undisclosed noncurrent assets | 5 | 109 | 7,799 | (2) | 54 | 63 | |||
| Total noncurrent assets: | 4,108 | 4,687 | 10,497 | 51 | 61 | 71 | |||
| Other undisclosed assets | 104 | 2 | 6 | 9 | |||||
| TOTAL ASSETS: | 4,212 | 5,323 | 11,314 | 1,692 | 2,089 | 2,192 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 1,073 | 775 | 218 | 442 | |||||
| Other undisclosed accounts payable and accrued liabilities | 1,073 | 775 | 218 | 442 | |||||
| Deferred revenue | ✕ | ✕ | |||||||
| Debt | 20 | 455 | 344 | 1,052 | 1,433 | 5,635 | |||
| Derivative instruments and hedges, liabilities | 1,649 | ||||||||
| Due to related parties | 1,527 | 1,650 | 1,606 | ||||||
| Other liabilities | 27 | 33 | 25 | 42 | 23 | 23 | |||
| Other undisclosed current liabilities | 1,697 | 2,093 | 54 | ||||||
| Total current liabilities: | 3,392 | 2,581 | 1,496 | 3,395 | 3,324 | 7,705 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 1,383 | ||||||||
| Long-term debt, excluding current maturities | 1,383 | ||||||||
| Finance lease, liability | ✕ | ✕ | |||||||
| Other undisclosed noncurrent liabilities | 4,262 | 5,081 | 8,252 | 5,057 | 4,847 | 772 | |||
| Total noncurrent liabilities: | 5,645 | 5,081 | 8,252 | 5,057 | 4,847 | 772 | |||
| Total liabilities: | 9,037 | 7,662 | 9,749 | 8,452 | 8,171 | 8,477 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (4,825) | (2,338) | 1,162 | (6,860) | (6,164) | (6,333) | |||
| Common stock | 19 | 14 | 13 | 6 | 6 | 5 | |||
| Common stock, share subscribed but unissued, subscriptions receivable | (46) | (4,530) | (202) | (50) | (41) | (24) | |||
| Additional paid in capital | 59,191 | 51,000 | 43,201 | 28,623 | 22,864 | 15,924 | |||
| Accumulated deficit | (64,125) | (57,882) | (41,850) | (35,440) | (28,992) | (22,238) | |||
| Stockholders' equity note, subscriptions receivable | |||||||||
| Other undisclosed equity, attributable to parent | 135 | 9,060 | |||||||
| Other undisclosed equity | 404 | 100 | 82 | 48 | |||||
| Total equity: | (4,825) | (2,338) | 1,566 | (6,760) | (6,082) | (6,284) | |||
| TOTAL LIABILITIES AND EQUITY: | 4,212 | 5,323 | 11,314 | 1,692 | 2,089 | 2,192 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 9 | 60 | 799 | 196 | 48 | |||
| Cost of revenue | (576) | (9) | (43) | |||||
| Gross profit: | 9 | 60 | 224 | 187 | 5 | |||
| Operating expenses | (4,662) | (14,035) | (4,949) | (6,729) | (5,223) | (3,154) | ||
| Operating loss: | (4,653) | (13,975) | (4,949) | (6,506) | (5,036) | (3,149) | ||
| Nonoperating income (expense) | 1,590 | 2,049 | (1,342) | 58 | (1,719) | (1,019) | ||
| Investment income, nonoperating | 239 | (86) | (75) | (1,123) | (704) | |||
| Other nonoperating income (expense) | 1,590 | |||||||
| Interest and debt expense | (140) | 1,587 | (1,158) | (249) | (140) | (315) | ||
| Loss from continuing operations before equity method investments, income taxes: | (3,203) | (10,339) | (7,449) | (6,696) | (6,894) | (4,483) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | (3,040) | (5,686) | 1,158 | 249 | 140 | 315 | ||
| Loss from continuing operations: | (6,243) | (16,024) | (6,291) | (6,448) | (6,755) | (4,168) | ||
| Loss before gain (loss) on sale of properties: | ✕ | (16,032) | (6,410) | (6,448) | (6,755) | (4,168) | ||
| Loss from discontinued operations | (8) | (119) | ||||||
| Other undisclosed net income | 12,486 | |||||||
| Net income (loss): | 6,243 | (16,032) | (6,410) | (6,448) | (6,755) | (4,168) | ||
| Other undisclosed net loss attributable to parent | (12,486) | |||||||
| Net loss available to common stockholders, diluted: | (6,243) | (16,032) | (6,410) | (6,448) | (6,755) | (4,168) | ||
Comprehensive Income ($ in thousands)
| 6/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 6,243 | (16,032) | (6,410) | (6,448) | (6,755) | (4,168) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | 6,243 | (16,032) | (6,410) | (6,448) | (6,755) | (4,168) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.